Showing 3231-3240 of 4063 results for "".
- Lenz Therapeutics Completes Merger with Graphite Bio; Debuts on Nasdaqhttps://modernod.com/news/lenz-therapeutics-completes-merger-with-graphite-bio-to-debut-on-nasdaq/2482177/Lenz Therapeutics announced the completion of its previously announced merger with Graphite Bio. The new combined company will operate under the name Lenz Therapeutics and will commence trading on Nasdaq under the ticker symbol “LENZ” on March 22, 2024. &ldquo
- Virtual Vision Health Unveils New Features for Virtual Eye Prohttps://modernod.com/news/virtual-vision-health-unveils-new-features-for-virtual-eye-pro/2482166/Virtual Vision Health has announced it will showcase new testing features on its Virtual Eye Pro at Vision Expo East and ASCRS 2024. Developed and validated at Bascom Palmer Eye Institute, the virtual reality visual field headset is designed to increase practice efficienc
- The Vision Council Releases New Research Highlighting U.S. Consumers’ Eyeglass Frames Preferenceshttps://modernod.com/news/the-vision-council-releases-new-research-highlighting-us-consumers-eyeglass-frames-preferences/2482152/The Vision Council released new research featuring insights into U.S. consumers’ experiences and preferences when purchasing new glasses frames. Findings from the report, "Focused inSights 2024 Frame Trends," underscore the diversity in eyewear preferences and purchase behaviors,
- SDC Transitions its Ophthalmic Biometric Division to Ora Inc.https://modernod.com/news/sdc-transitions-its-ophthalmic-biometric-division-to-ora-inc/2482149/Statistics & Data Corporation (SDC) has decided to transition its ophthalmic biometric division to its partner Ora Inc. Since 2005, SDC’s partnership and common ownership with Ora has provided clinical trial services in ophthalmology, while allowing S
- Amring Pharmaceuticals Changes Name to Nordic Pharma Under New Ownerhttps://modernod.com/news/amring-pharmaceuticals-changes-name-to-nordic-pharma-under-new-owner/2482141/Amring Pharmaceuticals has changed its name to Nordic Pharma, effective today, following the change in ownership of the company from Sever Life Sciences to Nordic Group, a subsidiary of Sever Life Sciences, which occurred on June 1, 2023. The change in the corporate name
- CorNeat EverPatch Synthetic Tissue Substitute Now Available in the UShttps://modernod.com/news/corneat-everpatch-synthetic-tissue-substitute-now-available-in-the-us/2482138/CorNeat Vision announced the commerical launch of the CorNeat EverPatch, a synthetic tissue-integrating matrix for ocular surface surgeries. The EverPatch, which received FDA 510(k) clearance in June 2023, offers a combination of features that provide an advantage over ex
- Oculis Provides Updates on Late-Stage Clinical Trials; Announces Leadership Appointmentshttps://modernod.com/news/oculis-provides-updates-on-late-stage-clinical-trials-announces-leadership-appointments/2482135/Oculis provided updates its late-stage clinical trials, and also announced senior appointments to its management and advisory teams. The announcements were made during it R&D Day on Wednesday, February 28. “2024 promises to be another exciting year for Ocu
- jCyte Announces Pre-Phase 3 Type B Meeting with FDA; Outlines Plans to Start Pivotal Trial of jCell for RPhttps://modernod.com/news/jcyte-announces-pre-phase-3-type-b-meeting-with-fda-outlines-plans-to-start-pivotal-trial-of-jcell-for-rp/2482126/jCyte announced the successful outcome of its pre-phase 3 Type B meeting with the FDA held on January 16, 2024. Additionally, the company is gearing up to commence its pivotal US trial for jCell for retinitis pigmentosa (RP) in the second half of 2024. John Sholar, Chief Executive
- Vision Integrated Partners Completes Refinancinghttps://modernod.com/news/vision-integrated-partners-completes-refinancing/2482123/Vision Integrated Partners (VIP) has successfully completed a recapitalization that consist of $25 million revolving credit facility, a $155 million term loan, and a $12.5 million delayed draw term loan. Proceeds from the credit facilities will be used to refinance existing indebte
- Meridian Medical Launches Line of Ophthalmic Lasers in the UShttps://modernod.com/news/meridian-medical-launches-line-of-ophthalmic-lasers-in-the-us/2482104/Following a series of FDA approvals, Switzerland-based Meridian Medical is launching its line of ophthalmic lasers in the US. On January 25, Meridian received FDA approval for the MR Q family of lasers. The lasers include: MR Q, a fully integrated ND:YAG laser combined